Bacteraemia in ventricular assist devices: a common complication that need not affect clinical outcomes.

BACKGROUND: Ventricular assist device (VAD) implantation has become an effective option for patients with severe heart failure. However, device-related infections remain a significant problem. The aim of this study was to describe the incidence and microbiological aetiology of bacteraemia in patients with VADs, and to assess the impact of bacteraemia on clinical outcomes. METHODS: A retrospective study was conducted of patients having VAD implantation at the Alfred Hospital (Melbourne, Australia) from October 1990 to July 2009. Medical records and microbiology databases were reviewed. Patients who were supported with a VAD for 72h or more were evaluated for demographic data, VAD type, the occurrence of bacteraemia and clinical outcomes. RESULTS: During the 19-year period, 135 VAD patients (89 Thoratec PVAD, 10 Novacor, and 36 Ventrassist) supported for a total duration of 17,304 (median 74) support days were included. Sixty-one patients (45%) developed VAD-associated bacteraemia, an incidence of 5.6 episodes per 1000 support days. The incidence of bacteraemia per 1000 days of support was similar for the three devices used: Thoratec PVAD, Novacor and Ventrassist VADs (7.8±0.8, 5.2±1.5 and 3.4±0.5, respectively, p=0.74). Staphylococcus aureus was the most common pathogen (25%). The rates of death on device, survival to transplant, recovery with explant and outcomes after transplantation, including 30-day mortality, median survival time and incidence of cerebrovascular accidents were not significantly impacted upon by bacteraemia. CONCLUSIONS: Bacteraemia is common in VAD patients. However, the incidence of VAD-associated bacteraemia is independent of device type and with aggressive antimicrobial therapy; clinical outcomes need not be affected by the bacteraemia.

Cost-utility analysis of sutureless and rapid deployment versus conventional aortic valve replacement in patients with moderate to severe aortic stenosis in Thailand.

BACKGROUND: Sutureless and rapid deployment aortic valve replacement (SUAVR) has become an alternative to conventional aortic valve replacement (CAVR) for aortic stenosis (AS) treatment due to its advantages in reducing surgery time and improving outcomes. This study aimed to assess the cost-utility of SUAVR vs. CAVR treatment for patients with moderate to severe AS in Thailand. METHODS: A two-part constructed model was used to estimate the lifetime costs and quality-adjusted life years (QALYs) from both societal and healthcare perspectives. Data on short-term mortality, complications, cost, and utility data were obtained from the Thai population. Long-term clinical data were derived from clinical studies. Costs and QALYs were discounted annually at 3% and presented as 2022 values. The incremental cost-effectiveness ratio (ICER) was calculated to determine additional cost per QALY gained. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: SUAVR treatment incurred higher costs compared with CAVR treatment from both societal (THB 1,733,355 [USD 147,897] vs THB 1,220,643 [USD 104,150]) and healthcare provider perspectives (THB 1,594,174 [USD 136,022] vs THB 1,065,460 [USD 90,910]). In addition, SUAVR treatment resulted in lower health outcomes, with 6.20 life-years (LYs) and 4.95 QALYs, while CAVR treatment achieved 6.29 LYs and 5.08 QALYs. SUAVR treatment was considered as a dominated treatment strategy using both perspectives. Sensitivity analyses indicated the significant impact of changes in utilities and long-term mortality on the model. CONCLUSION: SUAVR treatment is not a cost-effective treatment strategy compared with CAVR treatment for patients with moderate-severe AS in Thailand, as it leads to higher costs and inferior health outcomes. Other important issues related to specific patients such as those with minimally invasive surgery, those undergoing AVR with concomitant procedures, and those with calcified and small aortic root should be taken into account.

Trends in Economic Burden and Mortality of Hospitalized Patients With Aortic Stenosis in Thailand.

This study aimed to assess the temporal trends in aortic stenosis (AS)-related hospitalizations, in-hospital mortality, and economic burden in Thailand. The study cohort was derived from the electronic claim system of the National Health Security Office, which serves as a reimbursement database for all Thai beneficiaries under the Universal Health Coverage Scheme, covering ∼70% of the entire population. Hospitalization, mortality, and costs were estimated by year, with the primary diagnosis for AS-related hospitalizations identified using code I350. The Cochrane Armitage test was used to examine trends in AS-related hospitalization and in-hospital mortality, whereas a nonparametric trend test was used to analyze the trend of hospitalization costs. Of the 8-year period, 10,406 adults were admitted with a primary diagnosis of AS. AS-related hospitalizations increased from 1,274 in 2015 to 1,945 in 2022 (p = 0.251), with the most significant observed in the age group 60 to 79 years (p <0.001). In-hospital mortality increased from 4.8% to 6.1%. Hospitalization cost significantly increased from $2,879 to $3,443 (p <0.001), with an average length of stay of 6.6 ± 9.2 days. The trend of patients admitted with primary diagnosis of AS in Thailand has significantly increased in the age group 60 to 79 years. In-hospital admission is found at older age and is likely to have high mortality rate. The increased hospitalization cost may impose a substantial economic burden on the Thai health care system.

Giant coronary artery aneurysm mimicking a mediastinal mass: a case report and review.

Giant coronary artery aneurysm is a rare disorder which remains asymptomatic in most patients. However it appears that serious complications may develop at some point of time and will likely require surgical intervention. A patient with a huge coronary aneurysm ten centimeters in diameter successfully treated with surgical intervention was presented.

Cardiac myxoma: sixteen-year experience in Central Chest Institute of Thailand.

BACKGROUND: Among the rare diseases of primary cardiac tumor myxoma is a leading pathology. A sixteen-year clinical experience and follow-up ofpatients with surgical removal of this particular mass is reported. MATERIAL AND METHOD: Medical records of intracardiac tumor patients between April 1995 and June 2012 were reviewed and only cardiac myxoma patients who underwent surgical resection were studied The data of clinical presentations, investigations, operative details, and results were analyzed. RESULTS: Forty-five cardiac myxoma patients with a mean age of 52.6 +/- 2.3 (14 to 82) years were on operated during the sixteen-year period; of these, 76% were female. Dyspnea was the most common symptom accounting for approximately 78%,followed by heart failure 38%, and stroke 18%. Constitutional symptoms of weight loss, fatigue, and fever were found 33%, 13%, and 11%, respectively. Mean ejection fraction was 62% and the tumor size varied from 1.4 to 10 centimeters in diameter Site distribution of tumors were left atrium (89%), right atrium (9%), and multiple site (2%), with the interatrial septum as the most frequent site of attachment (69%). Patients with irregular surface tumors had 29% greater chance of having stroke than those with smooth surface tumors (p = 0.015). There was no operative or post-operative mortality. The complete follow-up was 98% with 99.8 +/- 52 months of mean follow-up. Ten and fifteen-year survival were 97%. A recurrence was found in one patient with multiple site tumors at eight-year follow-up. CONCLUSION: Myxoma is a rare disease with a variety of clinical presentation. Surgical resection provides excellent operative and long-term survival. Despite a very insignificant chance of recurrence, long-term follow-up is still necessary.

Impact of right ventricular pacing on right ventricular function.

BACKGROUND: The benefits of right ventricular pacing in patients with symptomatic bradycardia are well recognized. Currently, left ventricular (LV) function after cardiac pacing has already been extensively investigated. However existing data on right ventricular (RV) function in these patients is extremely limited. MATERIAL AND METHOD: To test this, records of RV and tricuspid valve function of patients with a pacemaker measured at least a year after implantation were reviewed for a prevalence of RV dysfunction. The patients were also divided into those with and without RV dysfunction. Factors affecting the two groups were evaluated. RESULTS: RV dysfunction and moderate to severe tricuspid valve regurgitation were found in approximately 4% and 21% respectively in cardiac pacing patients with mean implantation duration of 6.4 years. Compared to normal RV function, factors presumed to affect on RV dysfunction including site of pacing, pacing mode and percentage of ventricular pacing were not significantly different (p = 0.54, 0.37 and 0.12 respectively). CONCLUSION: Based on these data, the prevalence of right ventricular dysfunction appears to be infrequent and factors that were assumed as contributors to LV dysfunction failed to show significant contributions to RV dysfunction.

Patient-prosthesis mismatch has no influence on in-hospital mortality after aortic valve replacement.

OBJECTIVE: To analyze the relationship between prosthetic aortic valve orifice and body surface area (Effective Orifice Area Index, EOAI) and in-hospital mortality after aortic valve replacement. MATERIAL AND METHOD: A prospective study was conducted between October 2007 to September 2010, 536 patients underwent isolated aortic valve replacement (AVR) was recorded on preoperative, operative and postoperative data. Patient Prosthesis Mismatch (PPM) was classified by Effective Orifice Area Indexed (EOAI) by prosthetic valve area divided by body surface area as mild or no significance if the EOAI is greater than 0.85 cm2/m2, moderate if between 0.65 cm2/m2 and 0.85 cm2/m2, and severe if less than 0.65 cm2/m2. Statistical differences were analyzed by Chi-square and student t-test with p-value less than 0.05 considered significant. RESULTS: There were 304 men, mean age was 60.98 years, mean valve orifice area 1.69 cm2, body surface area 1.60 m2, cross clamp time 1.13 hrs., bypass time 1.67 hrs. Mechanical valves were used in 274 patients (51.2%) and Bioprosthesis were used in 181 patients (48.8%). PPM was found in 33.7%, 6.7% was severe PPM, 27% was moderate PPM and 66.3% has no significant PPM Over all in-hospital mortality was 1.5%. There was no significant difference in hospital mortality between no PPM group, moderate PPM and severe PPM group (1.4% vs. 1.4% vs. 5.4%, p-value = 0.86). CONCLUSION: In a large aortic valve surgery population, moderate and severe patient prosthesis mismatch occurred in 35.6% of patients but had no influence on in-hospital mortality.

Impending rupture of aortic aneurysm eroding skin and sternum: a rare condition.

A rare presentation of ascending aortic aneurysm eroding into the anterior chest wall and skin is described. Only a few reports of this lethal condition associated with luetic disease have been published previously. A 72-year-old man with a history of blunt chest injury subsequently developed a saccular aneurysm of the ascending aorta protruding out of the anterior chest wall. He was successfully treated with a surgical intervention.

Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials.

AIMS: Bone marrow stem cell (BMSC) treatment of ST-segment elevation myocardial infarction (STEMI) has been primarily via the intracoronary route or via endogenous mobilization using granulocyte colony-stimulating factor (G-CSF). Studies have provided conflicting results. We therefore performed a meta-analysis of these treatments, examining short- and long-term efficacy and safety. METHODS AND RESULTS: Randomized controlled trials (RCTs) of BMSC-based therapy for STEMI, delivered within 9 days of reperfusion, were identified by systematic search. Random effects models were used to calculate pooled effects of clinical outcomes, with meta-regression to assess dependence of the magnitude of effect sizes on study characteristics. Twenty-nine RCTs enrolling 1830 patients were included. Intracoronary BMSC therapy resulted in an overall improvement in left ventricular ejection fraction (LVEF) of 2.70% [95% confidence interval (CI) 1.48-3.92; P < 0.001] in the short term and 3.31% (95% CI 1.87-4.75; P < 0.001) longer term. Meta-regression suggested a dose-response relationship between quantity of CD34(+) cells delivered and increase in LVEF (P = 0.007). G-CSF treatment resulted in a trend towards similar benefits (P = 0.20). No significant differences were observed in pooled adverse outcome rates between intervention and control groups of either treatment approach, except for lower revascularization rates with intracoronary BMSC vs. control (odds ratio 0.68, 95% CI 0.47-0.97; P = 0.03). CONCLUSIONS: Intracoronary BMSC therapy post-STEMI improves LVEF beyond standard medical treatment, in both the short and longer term. G-CSF treatment shows positive but non-significant trends. Both treatments demonstrate safety comparable with conventional medical treatment.

Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography.

AIM: The impact of cardiac dysfunction on the liver is known as cardiac hepatopathy. In certain instances this can result in significant hepatic fibrosis or cirrhosis. The validity of non-invasive tools to assess hepatic fibrosis, such as FibroScan(®) which measures liver stiffness (LSM), has not been established in this setting. We examined the impact of cardiac dysfunction on LSM using FibroScan(®) and the influence of volume changes on LSM. METHODS AND RESULTS: A prospective, cross-sectional study examined the use of FibroScan(®) in subjects with left-sided heart failure (LHF, n = 32), right-sided heart failure (RHF, n = 9), and acute decompensated heart failure (ADHF, n = 8). The impact of volume changes upon LSM was further examined in the ADHF group (pre- and post-diuresis) and in a haemodialysis group (HD, n = 12), pre- and post-ultrafiltration on dialysis. Compared with healthy controls [n = 55, LSM = median 4.4 (25th percentile 3.6, 75th percentile 5.1) kPa], LSM was increased in all the cardiac dysfunction subgroups [LHF, 4.7 (4.0, 8.7) kPa, P = 0.04; RHF, 9.7 (5.0, 10.8) kPa, P < 0.001; ADHF, 11.2 (6.7, 14.3) kPa, P < 0.001]. Alteration in volume status via diuresis did not change the baseline LSM in ADHF [11.2 (6.7, 14.3) to 9.5 (7.3, 21.6) kPa, P > 0.05] with mean diuresis 5051 ± 1585 mL, or ultrafiltration in HD [6.0 (3.6, 5.1) vs. 5.7 (4.8, 7.0) kPa, P > 0.05] with mean diuresis 1962 ± 233 mL. CONCLUSION: Our findings support the concept of increased LSM in the cardiac failure population. LSM was not altered to a statistically significant level with acute volume changes.

Is target dose of beta-blocker more important than achieved heart rate or heart rate change in patients with systolic chronic heart failure?

Beta-blockers (BBs) are mandatory therapy for patients with systolic chronic heart failure (CHF). However, it is uncertain whether target dose of these agents is more important than the achievement of target heart rate (HR) in maximizing the benefits of these agents. To test this, we obtained ECG absolute HR from patients with systolic CHF, together with consecutive left ventricular ejection fraction (EF) measures at least 3 months apart. Patients were divided into those who achieved target dose for beta-blocker and/or target absolute HR of < or = 60 beats per minute (bpm) and target change in HR (>10 bpm reduction) with increasing dose. Baseline ejection fraction (EF) was similar across all groups. Patients with absolute or change in HR at target achieved a greater change in EF than those not at target (P= 0.027 and P= 0.012, respectively). In contrast, those who achieved target dose did not achieve a significantly greater improvement in EF than those not at target dose (P= 0.81). Similarly for absolute EF, patients at target HR or target change in HR achieved a greater EF increase than those achieving target dose. Based on these data, target HR or change in HR appears to be more critical to improvement in EF than target dose in CHF patients. Therefore, achieving an absolute HR or change in HR with BBs may be more important than target dose in maximizing benefits of BBs in this setting.

B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.

BACKGROUND: The use of plasma levels of B-type natriuretic peptides (BNPs) to guide treatment of patients with chronic heart failure (HF) has been investigated in a number of randomized controlled trials (RCTs). However, the benefits of this treatment approach have been uncertain. We therefore performed a meta-analysis to examine the overall effect of BNP-guided drug therapy on cardiovascular outcomes in patients with chronic HF. METHODS: We identified RCTs by systematic search of manuscripts, abstracts, and databases. Eligible RCTs were those that enrolled more than 20 patients and involved comparison of BNP-guided drug therapy vs usual clinical care of the patient with chronic HF in an outpatient setting. RESULTS: Eight RCTs with a total of 1726 patients and with a mean duration of 16 months (range, 3-24 months) were included in the meta-analysis. Overall, there was a significantly lower risk of all-cause mortality (relative risk [RR], 0.76; 95% confidence interval [CI], 0.63-0.91; P = .003) in the BNP-guided therapy group compared with the control group. In the subgroup of patients younger than 75 years, all-cause mortality was also significantly lower in the BNP-guided group (RR, 0.52; 95% CI, 0.33-0.82; P = .005). However, there was no reduction in mortality with BNP-guided therapy in patients 75 years or older (RR, 0.94; 95% CI, 0.71-1.25; P = .70). The risk of all-cause hospitalization and survival free of any hospitalization was not significantly different between groups (RR, 0.82; 95% CI, 0.64-1.05; P = .12 and RR, 1.07; 95% CI, 0.85-1.34; P = .58, respectively). The additional percentage of patients achieving target doses of angiotensin-converting enzyme inhibitors and beta-blockers during the course of these trials averaged 21% and 22% in the BNP group and 11.7% and 12.5% in the control group, respectively. CONCLUSIONS: B-type natriuretic peptide-guided therapy reduces all-cause mortality in patients with chronic HF compared with usual clinical care, especially in patients younger than 75 years. A component of this survival benefit may be due to increased use of agents proven to decrease mortality in chronic HF. However, there does not seem to be a reduction in all-cause hospitalization or an increase in survival free of hospitalization using this approach.